S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
Here's something only a handful of people know (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
Here's something only a handful of people know (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
Here's something only a handful of people know (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
Here's something only a handful of people know (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
NASDAQ:CRDF

Cardiff Oncology (CRDF) Stock Forecast, Price & News

$1.70
+0.06 (+3.66%)
(As of 06/6/2023 ET)
Compare
Today's Range
$1.61
$1.70
50-Day Range
$1.37
$1.95
52-Week Range
$1.20
$3.41
Volume
137,749 shs
Average Volume
210,643 shs
Market Capitalization
$75.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Cardiff Oncology MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
370.6% Upside
$8.00 Price Target
Short Interest
Healthy
1.21% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.09) to ($1.41) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

Medical Sector

527th out of 981 stocks

Biological Products, Except Diagnostic Industry

78th out of 152 stocks


CRDF stock logo

About Cardiff Oncology (NASDAQ:CRDF) Stock

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.

Receive CRDF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiff Oncology and its competitors with MarketBeat's FREE daily newsletter.

CRDF Stock News Headlines

The Stock That's Brining Lithium Back To America!
The American Energy Crisis Is Very Real And This Stock Is Solving That Problem On U.S Soil
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
Cardiff City
Championship side Cardiff hire Lamouchi as new boss
See More Headlines

CRDF Price History

CRDF Company Calendar

Last Earnings
5/04/2023
Today
6/06/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRDF
Fax
N/A
Employees
22
Year Founded
1999

Price Target and Rating

Average Stock Price Forecast
$8.00
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+370.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-38,700,000.00
Net Margins
-9,862.78%
Pretax Margin
-9,856.71%

Debt

Sales & Book Value

Annual Sales
$390,000.00
Book Value
$2.38 per share

Miscellaneous

Free Float
43,113,000
Market Cap
$75.96 million
Optionable
Not Optionable
Beta
1.76

Social Links


Key Executives

  • Mark ErlanderMark Erlander
    Chief Executive Officer & Director
  • Vicki KelemenVicki Kelemen
    Chief Operating Officer
  • James E. LevineJames E. Levine
    Chief Financial Officer
  • Tod Smeal
    Chief Scientific Officer
  • Fairooz Kabbinavar
    Chief Medical Officer













CRDF Stock - Frequently Asked Questions

Should I buy or sell Cardiff Oncology stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardiff Oncology in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRDF shares.
View CRDF analyst ratings
or view top-rated stocks.

What is Cardiff Oncology's stock price forecast for 2023?

3 brokerages have issued 1 year price targets for Cardiff Oncology's stock. Their CRDF share price forecasts range from $5.00 to $14.00. On average, they predict the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 370.6% from the stock's current price.
View analysts price targets for CRDF
or view top-rated stocks among Wall Street analysts.

How have CRDF shares performed in 2023?

Cardiff Oncology's stock was trading at $1.40 on January 1st, 2023. Since then, CRDF shares have increased by 21.4% and is now trading at $1.70.
View the best growth stocks for 2023 here
.

Are investors shorting Cardiff Oncology?

Cardiff Oncology saw a decrease in short interest in May. As of May 15th, there was short interest totaling 542,300 shares, a decrease of 12.1% from the April 30th total of 616,900 shares. Based on an average daily volume of 198,500 shares, the days-to-cover ratio is currently 2.7 days.
View Cardiff Oncology's Short Interest
.

When is Cardiff Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our CRDF earnings forecast
.

How were Cardiff Oncology's earnings last quarter?

Cardiff Oncology, Inc. (NASDAQ:CRDF) issued its quarterly earnings results on Thursday, May, 4th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.02. The company earned $0.08 million during the quarter, compared to analysts' expectations of $0.08 million. Cardiff Oncology had a negative trailing twelve-month return on equity of 35.70% and a negative net margin of 9,862.78%.

What other stocks do shareholders of Cardiff Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiff Oncology investors own include Sorrento Therapeutics (SRNE), Livongo Health (LVGO), Co-Diagnostics (CODX), Novavax (NVAX), Fortress Biotech (FBIO), Maxar Technologies (MAXR), Ontrak (OTRK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX) and Cassava Sciences (SAVA).

What is Cardiff Oncology's stock symbol?

Cardiff Oncology trades on the NASDAQ under the ticker symbol "CRDF."

Who are Cardiff Oncology's major shareholders?

Cardiff Oncology's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (1.70%), Citigroup Inc. (1.46%), Assenagon Asset Management S.A. (0.88%), Renaissance Technologies LLC (0.74%), Two Sigma Advisers LP (0.32%) and Blair William & Co. IL (0.29%). Insiders that own company stock include Gary W Pace, James E Levine, John P Brancaccio, Lale White, Mark Erlander, Renee P Tannenbaum, Rodney S Markin and Vicki Kelemen.
View institutional ownership trends
.

How do I buy shares of Cardiff Oncology?

Shares of CRDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cardiff Oncology's stock price today?

One share of CRDF stock can currently be purchased for approximately $1.70.

How much money does Cardiff Oncology make?

Cardiff Oncology (NASDAQ:CRDF) has a market capitalization of $75.96 million and generates $390,000.00 in revenue each year. The company earns $-38,700,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis.

How can I contact Cardiff Oncology?

Cardiff Oncology's mailing address is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. The official website for the company is cardiffoncology.com. The company can be reached via phone at (858) 952-7570 or via email at ir@cardiffoncology.com.

This page (NASDAQ:CRDF) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -